HU0004747D0 - - Google Patents

Info

Publication number
HU0004747D0
HU0004747D0 HU0004747A HUP0004747A HU0004747D0 HU 0004747 D0 HU0004747 D0 HU 0004747D0 HU 0004747 A HU0004747 A HU 0004747A HU P0004747 A HUP0004747 A HU P0004747A HU 0004747 D0 HU0004747 D0 HU 0004747D0
Authority
HU
Hungary
Application number
HU0004747A
Other languages
Hungarian (hu)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU0004747D0 publication Critical patent/HU0004747D0/hu
Publication of HUP0004747A2 publication Critical patent/HUP0004747A2/hu
Publication of HUP0004747A3 publication Critical patent/HUP0004747A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0004747A 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation HUP0004747A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (3)

Publication Number Publication Date
HU0004747D0 true HU0004747D0 (enExample) 2001-02-28
HUP0004747A2 HUP0004747A2 (hu) 2001-10-28
HUP0004747A3 HUP0004747A3 (en) 2002-12-28

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004747A HUP0004747A3 (en) 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation

Country Status (44)

Country Link
US (1) US6313142B1 (enExample)
EP (1) EP1125929B1 (enExample)
JP (1) JP3579345B2 (enExample)
KR (1) KR100408177B1 (enExample)
CN (1) CN1173953C (enExample)
AP (1) AP2000002011A0 (enExample)
AR (1) AR029775A1 (enExample)
AT (1) ATE315028T1 (enExample)
AU (1) AU784694B2 (enExample)
BG (1) BG105009A (enExample)
BR (1) BR0005636A (enExample)
CA (1) CA2327029C (enExample)
CO (1) CO5261552A1 (enExample)
CY (1) CY1104989T1 (enExample)
CZ (1) CZ20004407A3 (enExample)
DE (1) DE60025317T2 (enExample)
DK (1) DK1125929T3 (enExample)
DZ (1) DZ3079A1 (enExample)
EA (1) EA003668B1 (enExample)
EE (1) EE200000659A (enExample)
ES (1) ES2254109T3 (enExample)
GE (1) GEP20022798B (enExample)
GT (1) GT200000190A (enExample)
HN (1) HN2000000203A (enExample)
HR (1) HRP20000804A2 (enExample)
HU (1) HUP0004747A3 (enExample)
ID (1) ID28489A (enExample)
IL (1) IL139849A (enExample)
IS (1) IS5715A (enExample)
MA (1) MA25223A1 (enExample)
NO (1) NO20006039L (enExample)
NZ (1) NZ508509A (enExample)
OA (1) OA11494A (enExample)
PA (1) PA8503801A1 (enExample)
PE (1) PE20010913A1 (enExample)
PL (1) PL344208A1 (enExample)
SG (1) SG102603A1 (enExample)
SK (1) SK17792000A3 (enExample)
TN (1) TNSN00230A1 (enExample)
TW (1) TW591016B (enExample)
UA (1) UA65615C2 (enExample)
UY (1) UY26451A1 (enExample)
YU (1) YU71500A (enExample)
ZA (1) ZA200006947B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
AU2002361811A1 (en) 2001-12-19 2003-07-09 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
CA2480439C (en) * 2002-04-11 2012-08-21 Roar Holding Llc Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
JP2006513186A (ja) 2002-12-20 2006-04-20 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害剤およびｈｍｇ−ｃｏａレダクターゼ阻害剤を含む剤形
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
AU2004222434B2 (en) * 2003-03-17 2010-06-03 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
BRPI0408442A (pt) * 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
SI1670768T1 (sl) * 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
CA2570688A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US7951950B2 (en) * 2005-02-24 2011-05-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
CL2008000684A1 (es) 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (enExample) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
MA25223A1 (fr) 2001-07-02
KR100408177B1 (ko) 2003-12-01
GEP20022798B (en) 2002-09-25
CA2327029A1 (en) 2001-05-30
NZ508509A (en) 2001-06-29
DZ3079A1 (fr) 2004-10-24
OA11494A (en) 2004-05-07
DE60025317D1 (de) 2006-03-30
AU7178900A (en) 2001-05-31
EA200001129A2 (ru) 2001-06-25
IL139849A0 (en) 2002-02-10
ZA200006947B (en) 2002-05-27
CN1302800A (zh) 2001-07-11
AP2000002011A0 (en) 2000-12-31
AR029775A1 (es) 2003-07-16
DE60025317T2 (de) 2006-08-03
DK1125929T3 (da) 2006-04-03
NO20006039D0 (no) 2000-11-29
PE20010913A1 (es) 2001-09-10
BG105009A (en) 2001-11-30
TW591016B (en) 2004-06-11
UY26451A1 (es) 2001-06-29
PA8503801A1 (es) 2002-07-30
JP3579345B2 (ja) 2004-10-20
CZ20004407A3 (cs) 2002-06-12
EP1125929A1 (en) 2001-08-22
SK17792000A3 (sk) 2002-10-08
EE200000659A (et) 2001-08-15
IL139849A (en) 2006-10-31
HRP20000804A2 (en) 2001-06-30
JP2001163859A (ja) 2001-06-19
EA003668B1 (ru) 2003-08-28
NO20006039L (no) 2001-05-31
KR20010052012A (ko) 2001-06-25
GT200000190A (es) 2002-04-27
BR0005636A (pt) 2001-07-17
UA65615C2 (uk) 2004-04-15
TNSN00230A1 (fr) 2005-11-10
EA200001129A3 (ru) 2001-10-22
ES2254109T3 (es) 2006-06-16
EP1125929B1 (en) 2006-01-04
HUP0004747A2 (hu) 2001-10-28
PL344208A1 (en) 2001-06-04
CA2327029C (en) 2005-08-09
CY1104989T1 (el) 2010-03-03
US6313142B1 (en) 2001-11-06
CO5261552A1 (es) 2003-03-31
HN2000000203A (es) 2001-06-13
YU71500A (sh) 2003-02-28
IS5715A (is) 2001-05-31
AU784694B2 (en) 2006-06-01
HK1038007A1 (en) 2002-03-01
SG102603A1 (en) 2004-03-26
ID28489A (id) 2001-05-31
HUP0004747A3 (en) 2002-12-28
CN1173953C (zh) 2004-11-03
ATE315028T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
BE2018C020I2 (enExample)
BE2016C007I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
BE2013C001I2 (enExample)
BE2012C036I2 (enExample)
JP2002526326A5 (enExample)
BE1025464I2 (enExample)
BE2010C011I2 (enExample)
JP2002529806A5 (enExample)
BRPI0017527B8 (enExample)
JP2002529678A5 (enExample)
JP2002523192A5 (enExample)
BE2011C004I2 (enExample)
BRPI0001672A2 (enExample)
BRPI0001542A2 (enExample)
HU0004747D0 (enExample)
JP2002505538A5 (enExample)
BRPI0012675B8 (enExample)
BRPI0017522A2 (enExample)
BRPI0303609A (enExample)
BRPI9917761A2 (enExample)
BRMU7902607U2 (enExample)
JP2002527956A5 (enExample)

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees